Baricitinib:第一木菠萝抑制剂在欧洲批准用于治疗中度到重度特应性皮炎在成人患者。
文章的细节
-
引用
复制到剪贴板 -
x射线检验G, Simonetti O, Rizzetto G, Diotallevi F, Molinelli E, Offidani
Baricitinib:第一木菠萝抑制剂在欧洲批准用于治疗中度到重度特应性皮炎在成人患者。
医疗保健(巴塞尔)。2021年11月18日,9 (11)。pii: healthcare9111575。doi: 10.3390 / healthcare9111575。
- PubMed ID
-
34828623 (在PubMed]
- 文摘
-
背景:特应性皮炎(AD)是一种炎症性皮肤病,其特征是一个广泛的表型多样性导致非常复杂的病理生理学机制确定新的治疗目标,如janus kinasis(木菠萝)抑制剂。目的:评估baricitinib的疗效和安全性,欧洲第一木菠萝1和2抑制剂批准用于治疗成人患者严重的广告。方法:第三阶段的有效性和安全性数据研究属于微风广告计划。结果:结果从BREEZE-AD1 AD2、AD4 AD7显示Baricitib 4毫克的功效,口服药物,每天一次,作为单一疗法或结合局部皮质类固醇(TCS),占很大比例的患者主要实现端点IGA 0 - 1 (16.4% vs . 4.8%;13.8%和4.5%;21.7%和9.7%;30.6%比14.7%)和EASI75 (24.8% vs . 8.8%;21.1%和6.1%;31.5%和17.2%;47.7%比22.9%)在16周(W16)与安慰剂相比,分别。 Baricitinib showed rapid improvement in symptoms, starting from week 1 of treatment at 4 mg dosage, with a good safety profile. Nasopharyngitis, upper respiratory tract infections (URIs), creatine phosphokinase (CPK) elevations, and headache were the most frequently reported adverse events. Conclusions: Following the efficacy and safety data on W 16 from the phase III BREEZE-AD studies, baricitinib has recently been approved in Europe for the treatment of moderate to severe AD in adult patients. Further data to evaluate long-term efficacy and safety in a real-life setting are needed.
DrugBank数据引用了这篇文章
- 药物